论文部分内容阅读
目的:观察复方丹参滴丸联合氯吡格雷对冠心病临床症状、心功能、心电图、C反应蛋白、血流变以及血小板聚集率的影响。方法:选取山东省青岛即墨市人民医院2013年1月~2015年4月接受治疗的冠心病患者80例,采用随机化分为2组,每组40例,两组患者均给予单硝酸异山梨酯片、阿托伐他丁钙片等基础治疗,在此基础上对照组患者给予阿司匹林联合氯吡格雷治疗,观察组给予复方丹参滴丸联合氯吡格雷进行治疗,两组患者均治疗6个月,观察对比两组治疗后临床症状、心功能、心电图、C反应蛋白、血流变以及血小板聚集率的情况。结果:治疗后与对照组比较,患者全血粘度高、中、低切及血浆粘度、血小板粘附率、全血还原粘度、CRP、血小板聚集率显著降低(P<0.01);观察组临床症状、心功能、心律失常以及心电图ST段改善时间显著短于对照组(P<0.05)。观察组总有效率为92.5%,显著高于对照组的70%(P<0.05)。结论:复方丹参滴丸联合氯吡格雷能有效抑制血小板聚集、减轻冠心病患者循环障碍,具有较高的临床疗效。
Objective: To observe the effects of compound Danshen dripping pills combined with clopidogrel on clinical symptoms, cardiac function, electrocardiogram, C-reactive protein, hemorrheology and platelet aggregation in patients with coronary heart disease. Methods: Eighty patients with coronary heart disease underwent treatment from January 2013 to April 2015 in Jimo People’s Hospital of Qingdao, Shandong Province. The patients were randomly divided into 2 groups (n = 40 in each group). Both groups were given isosorbide mononitrate Ester tablets, atorvastatin calcium tablets and other basic treatment, on the basis of the control group patients given aspirin combined with clopidogrel treatment, the observation group given compound Danshen dripping pills combined with clopidogrel for treatment, two groups of patients were treated 6 Month, observe and compare the clinical symptoms, cardiac function, electrocardiogram, C-reactive protein, hemorrheology and platelet aggregation rate after treatment in both groups. Results: Compared with the control group, the whole blood viscosity, platelet viscosity, platelet adhesion rate, whole blood viscosity, CRP and platelet aggregation rate were significantly decreased (P <0.01) after treatment. The clinical symptoms , Cardiac function, arrhythmia and ECG ST segment improvement time was significantly shorter than the control group (P <0.05). The total effective rate in the observation group was 92.5%, which was significantly higher than that in the control group (P <0.05). Conclusion: Compound Danshen dripping pills combined with clopidogrel can effectively inhibit platelet aggregation and reduce circulatory disturbance in patients with coronary heart disease, with a high clinical efficacy.